Recovery
KPV
Lys-Pro-Val tripeptide (alpha-MSH 11-13)
KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone that has shown anti-inflammatory activity in lab and animal models. It is not FDA-approved, and its research is still largely preclinical.
Key facts
- Commonly discussed for: gut inflammation and wound healing.
- Evidence (D): The core evidence is cell-culture work and mouse colitis models (DSS, TNBS and transfer colitis) published in Gastroenterology and Inflammatory Bowel Diseases in 2008. No controlled human trials were found.
- FDA status: PCAC recommended. On July 23, 2026 the PCAC voted 8-6 (1 abstention) to recommend KPV for the 503A Bulks List for wound healing and inflammatory conditions. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
- Legitimate access: Prescription compounding under an interim HHS policy (not FDA-approved).
- Last reviewed: October 1, 2026.
Read the deep dives
Sources
- Dalmasso et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008
- Kannengiesser et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD. Inflamm Bowel Dis, 2008
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- Federal Register notice of PCAC meeting and uses under review (April 16, 2026)